Adrenocorticotropic Hormone [ACTH] Market Size Report, 2022-2030
The global Adrenocorticotropic Hormone [ACTH] market gathered revenue around USD 2.1 billion in 2021 and market is set to grow USD 4.7 billion by the end of 2030 and is estimated to expand at a modest CAGR of 3.7% during the prediction period 2022 to 2030.
Need for the development of newer and technologically enhanced products is rising globally, owing to treatment efficiency of drugs. Hence, major players operating in the market invest in research & development in order to develop new drugs. The rise in investments in research & development by key players is anticipated to propel the global adrenocorticotropic hormone (ACTH) market.
Report Scope of the Adrenocorticotropic Hormone [ACTH] Market
|
Report Coverage |
Details |
|
Market Size |
US$ 4.7 Billion by 2030 |
|
Growth Rate |
CAGR of 3.7% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Source, Indication, Distribution Channel and Region, |
|
Companies Mentioned |
Mallinckrodt plc, Pfizer, Inc., Novartis AG, Merck KGaA, Ferring B.V., Avantor, Inc., Viatris, Inc., and Hikma Pharmaceuticals plc. |
Multiple Applications, Rise in Prevalence of Chronic Diseases to Drive Global Market
H.P. Acthar Gel was Questcor Pharmaceuticals, Inc.'s primary corticotropin product, which was acquired by Mallinckrodt in August 2014. The U.S. FDA approved Acthar for the treatment of 19 indications. The rate of infantile spasm is estimated to be 2.5 to 6.0 per 10,000 live births. Its prevalence rate is 1.5 to 2.0 per 10,000 children aged 10 years or younger, based on data published in the National Organization for Rare Disorders, Inc. According to the Centers for Disease Control and Prevention (CDC), about 23% adults in the U.S., which is more than 54 million people, have arthritis. The disease is expected to affect 78 million adults in the country by 2040.
According to data published in the National Center for Biotechnology Information in 2019, the estimated prevalence of polymyositis and dermatomyositis (PM/DM) is 5 to 22 per 100,000 people, and approximately 1.2 million to 1.9 million people are at risk per year.
Adrenocorticotropic hormone (ACTH) has re-emerged as a treatment for proteinuria due to nephrotic syndrome (NS) in the last decade. Nephrotic syndrome is one of the most common chronic renal diseases in children. It has an incidence of 2 to 7 per 100,000 and a prevalence of 16 per 100,000, well above the 1 per 1 million incidence of chronic renal failure in children. Hence, rise in cases of target diseases and applications of corticotropin in various indications boost the growth of the global market.
Natural Source to Dominate Global Market
In terms of source, the global adrenocorticotropic hormone (ACTH) market has been bifurcated into natural and synthetic. The natural segment dominated the global adrenocorticotropic hormone (ACTH) market in 2020, and the trend is projected to continue during the forecast period.
Rheumatology to Gain Market Share, Offer Lucrative Opportunities
Based on indication, the global market has been classified into rheumatology, neurology, nephrotic syndrome, ophthalmology, and others. Arthritis is a chronic autoimmune disorder that causes flare up, stiffness, and swelling in the joints, especially in the lower extremities. Common types of arthritis are osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and gout. Arthritis is a wide term covering around 100 types of joint diseases. Several patients with psoriasis develop arthritis. All these factors are expected to drive the rheumatology segment.
Hospital Pharmacies to be Highly Lucrative Distribution Channel
Based on distribution channel, the global adrenocorticotropic hormone (ACTH) market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global adrenocorticotropic hormone (ACTH) market, and the trend is anticipated to continue during the forecast period. The rise in the adoption of e-commerce is anticipated to propel the online pharmacies segment in the near future.
North America to Lead Adrenocorticotropic Hormone (ACTH) Market
North America dominated the global adrenocorticotropic hormone (ACTH) market in 2020 and the trend is likely to continue during the forecast period. The dominance of North America in the global market can be attributed to high rate of adoption of Acthar Gel in a number of indications as well as high cost of the drug in the region.
The market in Europe is projected to expand at a CAGR of 6.98 from 2022 to 2030. Increase in awareness about various diseases, favorable medical reimbursement policies, availability of synthetic ACTH (tetracosactide), and well-established healthcare facilities are the major factors anticipated to drive the market in Europe during the forecast period.
Some of the prominent players in the Adrenocorticotropic Hormone [ACTH] Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Global Adrenocorticotropic Hormone (ACTH) Market: Segmentation
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Adrenocorticotropic Hormone [ACTH] Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Adrenocorticotropic Hormone (ACTH) Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Top 3 Players Operating in the Market Space
5.2. Regulatory Scenario
5.3. Export-Import Scenario
5.4. Comparison Study of Synthetic & Natural Adrenocorticotropic Hormone
5.5. Pipeline Analysis
5.6. COVID-19 Pandemic Impact on Industry
6. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Source
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Source, 2017–2030
6.3.1. Natural
6.3.2. Synthetic
6.4. Market Attractiveness Analysis, by Source
7. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2030
7.3.1. Rheumatology
7.3.2. Neurology
7.3.3. Nephrotic Syndrome
7.3.4. Ophthalmology
7.3.5. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2030
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Source, 2017–2030
10.2.1. Natural
10.2.2. Synthetic
10.3. Market Value Forecast, by Indication, 2017–2030
10.3.1. Rheumatology
10.3.2. Neurology
10.3.3. Nephrotic Syndrome
10.3.4. Ophthalmology
10.3.5. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2030
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Source
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Source, 2017–2030
11.2.1. Natural
11.2.2. Synthetic
11.3. Market Value Forecast, by Indication, 2017–2030
11.3.1. Rheumatology
11.3.2. Neurology
11.3.3. Nephrotic Syndrome
11.3.4. Ophthalmology
11.3.5. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2030
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-Region, 2017–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Source
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-Region
12. Asia Pacific Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Source, 2017–2030
12.2.1. Natural
12.2.2. Synthetic
12.3. Market Value Forecast, by Indication, 2017–2030
12.3.1. Rheumatology
12.3.2. Neurology
12.3.3. Nephrotic Syndrome
12.3.4. Ophthalmology
12.3.5. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2030
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-Region, 2017–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Source
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-Region
13. Latin America Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Source, 2017–2030
13.2.1. Natural
13.2.2. Synthetic
13.3. Market Value Forecast, by Indication, 2017–2030
13.3.1. Rheumatology
13.3.2. Neurology
13.3.3. Nephrotic Syndrome
13.3.4. Ophthalmology
13.3.5. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2030
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-Region, 2017–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Source
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-Region
14. Middle East & Africa Adrenocorticotropic Hormone (ACTH) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Source, 2017–2030
14.2.1. Natural
14.2.2. Synthetic
14.3. Market Value Forecast, by Indication, 2017–2030
14.3.1. Rheumatology
14.3.2. Neurology
14.3.3. Nephrotic Syndrome
14.3.4. Ophthalmology
14.3.5. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2030
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-Region, 2017–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Source
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-Region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Company Profiles
15.3.1. Ambio Pharm, Inc.
15.3.1.1. Company Description
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Armor Pharma
15.3.2.1. Company Description
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Avantor, Inc.
15.3.3.1. Company Description
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. BCN Peptides S.A.
15.3.4.1. Company Description
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. BIOVECTRA
15.3.5.1. Company Description
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Ferring B.V.
15.3.6.1. Company Description
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Hikma Pharmaceuticals plc
15.3.7.1. Company Description
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Mallinckrodt Pharmaceuticals
15.3.8.1. Company Description
15.3.8.2. Business Overview
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Merck KGaA
15.3.9.1. Company Description
15.3.9.2. Business Overview
15.3.9.3. Financial Overview
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
15.3.10. Novartis AG
15.3.10.1. Company Description
15.3.10.2. Business Overview
15.3.10.3. Financial Overview
15.3.10.4. Strategic Overview
15.3.10.5. SWOT Analysis
15.3.11. Novus Biologicals
15.3.11.1. Company Description
15.3.11.2. Business Overview
15.3.11.3. Financial Overview
15.3.11.4. Strategic Overview
15.3.11.5. SWOT Analysis
15.3.12. Pfizer, Inc.
15.3.12.1. Company Description
15.3.12.2. Business Overview
15.3.12.3. Financial Overview
15.3.12.4. Strategic Overview
15.3.12.5. SWOT Analysis
15.3.13. Piramal Pharma Solutions
15.3.13.1. Company Description
15.3.13.2. Business Overview
15.3.13.3. Financial Overview
15.3.13.4. Strategic Overview
15.3.13.5. SWOT Analysis
15.3.14. PolyPeptide Group
15.3.14.1. Company Description
15.3.14.2. Business Overview
15.3.14.3. Financial Overview
15.3.14.4. Strategic Overview
15.3.14.5. SWOT Analysis
15.3.15. SAJJALA BIO LABS
15.3.15.1. Company Description
15.3.15.2. Business Overview
15.3.15.3. Financial Overview
15.3.15.4. Strategic Overview
15.3.15.5. SWOT Analysis
15.3.16. Sichuan Xieli Pharmaceutical Co., Ltd.
15.3.16.1. Company Description
15.3.16.2. Business Overview
15.3.16.3. Financial Overview
15.3.16.4. Strategic Overview
15.3.16.5. SWOT Analysis
15.3.17. Viatris Inc.
15.3.17.1. Company Description
15.3.17.2. Business Overview
15.3.17.3. Financial Overview
15.3.17.4. Strategic Overview
15.3.17.5. SWOT Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers